V. Milacic, S. Banerjee, K. R. Landis-piwowar, F. H. Sarkar, A. P. Majumdar et al., Curcumin inhibits the proteasome activity in human colon cancer cells in vitro and in vivo, Cancer Res, vol.18, pp.7283-92, 2008.


S. Shishodia, H. M. Amin, R. Lai, and B. B. Aggarwal, Curcumin (diferuloylmethane) inhibits constitutive NF-kap-paB activation, induces G1/S arrest, suppresses proliferation and induces apoptosis in mantle cell lymphoma, Biochem Pharmacol, vol.5, pp.700-713, 2005.


A. C. Bharti, S. Shishodia, J. Reuben, D. Weber, R. Alexanian et al., Nuclear factor-kB and STAT3 are constitutively active in CD138 C cells derived from multiple myeloma patients, and suppression of these transcription factors leads to apoptosis, Blood, vol.103, pp.3175-84, 2004.


A. C. Bharti, N. Donato, and B. B. Aggarwal, Curcumin (diferuloylmethane) inhibits constitutive and IL-6-inducible STAT3 phosphorylation in human myeloma cells, J Immunol, vol.171, pp.3863-71, 2003.


J. Park, V. Ayyappan, E. K. Bae, C. Lee, B. S. Kim et al., Curcumin in combination with bortezomib synergistically induced apoptosis in human multiple myeloma U266 cells, Mol Oncol, vol.2, pp.317-343, 2008.

B. Sung, G. S. Kunnumakkara, G. Sethi, P. Anand, S. Gluha et al., Curcumin circumvents chemoresistance in vitro and potentiates the effect of thalidomide and botezomib against human multiple myeloma in nude mice model, Mol Cancer Ther, vol.8, pp.959-70, 2009.


F. Zhan, Y. Huang, S. Colla, J. P. Stewart, I. Hanamura et al., The molecular classification of multiple myeloma, Blood, vol.108, pp.2020-2048, 2006.

M. Chesi and P. L. Bergsagel, Molecular pathogenesis of multiple myeloma: basic and clinical updates, Int J Hematol, vol.97, pp.313-336, 2013.

S. K. Johnson, C. J. Heuck, A. P. Albino, P. Qu, Q. Zhang et al., The use of molecular-base risk stratification and pharmacogenomics for outcome prediction and personalized therapeutic management of multiple myeloma, Int J Hematol, vol.94, pp.321-354, 2011.


S. Wuill-eme-toumi, N. Robillard, P. Gomez, P. Moreau, L. Gouill et al., Mcl -1 is overexpressed in multiple myeloma and associated with relapse and shorter survival, Leukemia, vol.9, pp.1248-52, 2005.

A. S. Azmi, Z. Wang, P. A. Philip, R. M. Mohammad, and F. H. Sarkar, Emerging Bcl -2 inhibitors for the treatment of cancer, Expert Opin Emerg Drugs, vol.1, pp.59-70, 2011.


S. Surget, D. Chiron, P. Gomez-bougie, G. Descamps, E. Bataille et al., Cell Death via DR5, but not DR4, is regulated by p53 in myeloma cells, Cancer Res, vol.17, pp.4562-73, 2012.

M. Jourdan, M. Ferlin, E. Legouffe, M. Horvathova, J. Liautard et al., The myeloma cell antigen syndecan-1 is lost by apoptotic myeloma cells, Br J Haematol, vol.100, pp.637-683, 1998.


S. Derenne, B. Monia, N. M. Dean, J. K. Taylor, M. J. Rapp et al., Antisense strategy shows that Mcl -1 rather than Bcl -2 or Bcl -x(L) is an essential survival protein of human myeloma cells, Blood, vol.100, pp.194-99, 2002.

L. Bodet, P. Gomez-bougie, C. Touzeau, C. Dousset, G. Descamps et al., ABT-737 is highly effective against molecular subgroups of multiple myeloma, Blood, vol.118, pp.3901-3911, 2011.

P. Gomez-bougie and M. Amiot, Apoptotic machinery diversity in multiple myeloma molecular subtypes

, Front Immunol, vol.4, pp.1-6, 2013.

S. Surget, E. Lemieux-blanchard, S. Ma?-iga, G. Descamps, L. Gouill et al., Bendamustine and melphalan kill myeloma cells similarly through reactive oxygen species production and activation of the p53 pathway and do not overcome resistance to each other, Leuk Lymphoma, 2014.

P. Moreau, H. Avet-loiseau, J. L. Harousseau, and M. Attal, Current trends in autologous stem-cell transplantation for myeloma in the era of novel therapies, J Clin Oncol, vol.9, pp.1898-1904, 2011.

L. Lod-e, M. Eveillard, V. Trichet, T. Soussi, S. Wuill-eme et al., Mutations in TP53 are exclusively associated with del(17p) in multiple myeloma, Haematologica, vol.95, pp.1973-76, 2010.

J. A. Bush, K. J. Cheung, and G. Li, Curcumin induces apoptosis in human melanoma cells through a Fas/receptor/caspase-8 pathway independent of p53, Exp Cell Res, vol.2, pp.305-319, 2001.

T. Golombick, T. H. Diamond, A. Manoharan, and R. Ramakrishna, Monoclonal gammopathy of undetermined significance, smoldering multiple myeloma, and curcumin: A randomized, double-blind placebo controlled crossover 4g study and an open-label 8g extension study, Am J Hematol, vol.5, pp.455-60, 2012.

J. Moreaux, B. Klein, R. Bataille, G. Descamps, S. Ma?-iga et al., A high-risk signature for patients with multiple myeloma established from the molecular classification of human myeloma cell lines, Haematologica, vol.4, pp.574-82, 2011.
URL : https://hal.archives-ouvertes.fr/inserm-00550232

P. Gomez-bougie, S. Wuill-eme-toumi, E. Trichet, V. Robillard, N. et al., Noxa up-regulation and Mcl -1 cleavage are associated to apoptosis induction by bortezomib in multiple myeloma, Cancer Res, vol.67, pp.5418-5442, 2007.